T3 Tablets by British Dragon

T4 (Levothyroxine) is the storage and transport form of thyroid hormone — produced abundantly by the thyroid gland and converted to T3 in peripheral tissues on demand. T3 (Liothyronine) is the active form that binds thyroid receptors and produces the metabolic effects. The practical differences for performance use are significant: T3 is approximately four times more potent than T4 per unit of dose; T3 has a half-life of 1–2 days versus T4's 6–7 days, providing faster onset and a more responsive dose-effect relationship; and T3 bypasses the conversion step entirely, meaning its effects are not subject to individual variation in T4-to-T3 conversion efficiency. For rapid, controllable, dose-adjustable fat loss support, T3 is the pharmacologically appropriate choice over T4.

No. The thyroid system responds to sudden supraphysiological T3 introduction with acute cardiovascular and neurological effects — tachycardia, palpitations, tremors, anxiety, and insomnia — that are uncomfortable, potentially dangerous, and entirely avoidable with proper dose escalation. More importantly, starting high does not improve the fat loss outcome: the body's metabolic upregulation from T3 follows a trajectory that requires receptor saturation and adaptive enzyme upregulation, not just immediate peak exposure. A two-week ramp-up produces the same steady-state metabolic rate as starting high, with a fraction of the acute side effect burden. The descending taper at cycle end is equally non-negotiable — abrupt discontinuation after thyroid axis suppression causes rebound hypothyroidism that can persist for weeks and produce the full symptomatic picture of an underactive thyroid: fatigue, weight gain, brain fog, and depression.

At 25 mcg/day (physiological replacement range), lean tissue loss from T3 is minimal and anabolic protection is not strictly required for short cycles. At 50–75 mcg/day across 6–8 weeks — the performance fat loss dose range — lean tissue catabolism is measurable and meaningful without anabolic support. Research in clinical populations shows that supraphysiological T3 increases protein breakdown rates alongside fat mobilisation. For an athlete in a caloric deficit, who is already in a mild catabolic state by definition, adding T3-driven protein catabolism on top of diet-induced catabolism without anabolic counter-stimulation produces lean mass losses that compromise the physique outcome the fat loss was meant to improve. A testosterone base at performance doses is the standard minimum protection. It is not overstated — the catabolic effect of T3 at fat-loss doses is well documented and the practical lean tissue loss in unsupported cycles is consistently reported by athletes.

T3 and Clenbuterol are the most commonly combined fat-loss agents in performance protocols precisely because their mechanisms do not overlap. T3 increases basal metabolic rate through thyroid receptor activation — a genomic mechanism that alters cellular energy metabolism over days to weeks. Clenbuterol stimulates beta-2 adrenergic receptors to increase thermogenesis and lipolysis — a rapid non-genomic mechanism active within minutes of dosing. The two compounds address fat oxidation through different receptor systems, different time courses, and different biochemical pathways. Running them together produces additive fat loss above what either achieves alone. The practical management consideration: Clenbuterol beta-receptor downregulation requires cycling (2 weeks on, 2 weeks off) to remain effective; T3 is run continuously across the full cycle pyramid. The cardiovascular burden of both compounds together — elevated heart rate from Clenbuterol combined with T3-driven tachycardia — requires careful cardiac monitoring and dose conservatism, particularly in the first week of concurrent use.

Recovery timeline depends on cycle duration and peak dose. After a properly pyramided 8-week cycle peaking at 75 mcg/day, with a correctly executed taper, most athletes experience full HPT axis recovery within 4–8 weeks of completing the taper. The returning TSH signal restimulates thyroid T4 and T3 production progressively. In athletes with healthy pre-cycle thyroid function and correct pyramid execution, recovery is typically complete with no lasting thyroid impairment. Athletes who used very high doses (100+ mcg/day) for extended periods (12+ weeks) without adequate tapering may experience a prolonged recovery period. The most reliable indicator of recovery is not symptom assessment but bloodwork: TSH, free T3, and free T4 levels measured 4–6 weeks post-taper confirm whether the axis has fully normalised before planning a subsequent cycle.

Most users notice the first effects within the first one to two weeks of dosing.

The side profile depends on the compound class - the Side Effects section on the product page above covers the exact watchpoints for t3.

Oral compounds clear within days of the last dose; injectable esters extend detection to weeks or months depending on the ester.

British Dragon T3 Tablets is available in this shop with international and domestic shipping.